Phio Pharmaceuticals (PHIO) Income from Continuing Operations (2016 - 2020)
Historic Income from Continuing Operations for Phio Pharmaceuticals (PHIO) over the last 9 years, with Q4 2020 value amounting to -$2.5 million.
- Phio Pharmaceuticals' Income from Continuing Operations rose 775.57% to -$2.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$8.8 million, marking a year-over-year increase of 215.87%. This contributed to the annual value of -$11.5 million for FY2022, which is 1359.98% up from last year.
- Latest data reveals that Phio Pharmaceuticals reported Income from Continuing Operations of -$2.5 million as of Q4 2020, which was up 775.57% from -$2.3 million recorded in Q3 2020.
- In the past 5 years, Phio Pharmaceuticals' Income from Continuing Operations ranged from a high of -$1.5 million in Q3 2018 and a low of -$5.5 million during Q1 2017
- In the last 5 years, Phio Pharmaceuticals' Income from Continuing Operations had a median value of -$2.2 million in 2016 and averaged -$2.3 million.
- Per our database at Business Quant, Phio Pharmaceuticals' Income from Continuing Operations tumbled by 14473.33% in 2017 and then surged by 5899.27% in 2018.
- Phio Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$2.3 million in 2016, then rose by 14.41% to -$2.0 million in 2017, then grew by 13.74% to -$1.7 million in 2018, then crashed by 54.55% to -$2.7 million in 2019, then increased by 7.76% to -$2.5 million in 2020.
- Its last three reported values are -$2.5 million in Q4 2020, -$2.3 million for Q3 2020, and -$1.7 million during Q2 2020.